LEGEND BIOTECH SP.ADS/2
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of mult… Read more
Market Cap & Net Worth: LEGEND BIOTECH SP.ADS/2 (9LB)
LEGEND BIOTECH SP.ADS/2 (F:9LB) has a market capitalization of $3.03 Billion (€2.96 Billion) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #4103 globally and #400 in its home market, demonstrating a -2.44% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying LEGEND BIOTECH SP.ADS/2's stock price €16.00 by its total outstanding shares 184689565 (184.69 Million).
LEGEND BIOTECH SP.ADS/2 Market Cap History: 2020 to 2026
LEGEND BIOTECH SP.ADS/2's market capitalization history from 2020 to 2026. Data shows change from $4.44 Billion to $3.03 Billion (-7.36% CAGR).
LEGEND BIOTECH SP.ADS/2 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how LEGEND BIOTECH SP.ADS/2's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 9LB by Market Capitalization
Companies near LEGEND BIOTECH SP.ADS/2 in the global market cap rankings as of March 19, 2026.
Key companies related to LEGEND BIOTECH SP.ADS/2 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
LEGEND BIOTECH SP.ADS/2 Historical Marketcap From 2020 to 2026
Between 2020 and today, LEGEND BIOTECH SP.ADS/2's market cap moved from $4.44 Billion to $ 3.03 Billion, with a yearly change of -7.36%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €3.03 Billion | -13.51% |
| 2025 | €3.51 Billion | -41.46% |
| 2024 | €5.99 Billion | -41.48% |
| 2023 | €10.24 Billion | +16.38% |
| 2022 | €8.80 Billion | +11.54% |
| 2021 | €7.89 Billion | +77.78% |
| 2020 | €4.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of LEGEND BIOTECH SP.ADS/2 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.03 Billion USD |
| MoneyControl | $3.03 Billion USD |
| MarketWatch | $3.03 Billion USD |
| marketcap.company | $3.03 Billion USD |
| Reuters | $3.03 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.